Tizanidine Tablet
Product Images NDC 72578-097

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Tizanidine (NDC 72578-097). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Viona Pharmaceuticals Inc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure (8084032c 1645 44ae Bd4e 840a4a7abbe8 01)

Chemical structure of tizanidine hydrochloride showing its molecular arrangement with chlorine, nitrogen, sulfur atoms, and a fused ring system.*

FDA Label Image

Figure (8084032c 1645 44ae Bd4e 840a4a7abbe8 02)

A pharmacokinetic curve showing plasma tizanidine concentration (ng/mL) over time (hours) from dosing. The graph compares 2 x 4 mg tizanidine tablets and capsules, both with and without food, illustrating changes in drug concentration in plasma over a 24-hour period after oral administration.*

FDA Label Image

Figure (8084032c 1645 44ae Bd4e 840a4a7abbe8 03)

A line graph depicting improvement in Ashworth Score versus hours post-dose, comparing the effects of 16 mg tizanidine, 8 mg tizanidine, and placebo over a 6-hour period. The graph shows mean improvement scores with error bars for each treatment group at multiple time points.*

FDA Label Image

Figure (8084032c 1645 44ae Bd4e 840a4a7abbe8 04)

A line graph showing improvement in Ashworth Score over time comparing tizanidine (mean dose 28.8 mg) versus placebo. The x-axis represents study weeks (End of Titration at Week 3, End of Maintenance at Week 7, and Endpoint with last observation carried forward). The y-axis shows improvement in Ashworth Score with values ranging from -6 to 2, indicating greater improvement with tizanidine compared to placebo throughout the study period.*

FDA Label Image

Figure (8084032c 1645 44ae Bd4e 840a4a7abbe8 05)

Label for Tizanidine Tablets USP 2 mg by Viona Pharmaceuticals Inc. The white label with purple accents states each tablet contains 2.29 mg tizanidine hydrochloride equivalent to 2 mg tizanidine base. The package contains 150 tablets and is for prescription use only. Manufacturer is Cadila Healthcare Ltd., India, with distribution by Viona Pharmaceuticals Inc., Cranford, NJ. Includes storage instructions and child-resistant packaging notice.*

FDA Label Image

Figure (8084032c 1645 44ae Bd4e 840a4a7abbe8 06)

Label for Tizanidine Tablets USP 4 mg by Viona Pharmaceuticals Inc. The label indicates the package contains 150 tablets and is for prescription use only. It lists the strength as 4 mg tizanidine hydrochloride equivalent to 4 mg tizanidine base per tablet. Additional details include child-resistant packaging and storage instructions. Manufacturer and distributor information is also shown.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.